Regression of paclitaxel-induced maculopathy with oral acetazolamide

  • Kerstin Maria MeyerEmail author
  • Thomas Klink
  • Selma Ugurel
  • Eva-Bettina Bröcker
Letter to the Editor


Malignant melanoma is a highly aggressive skin cancer, characterized by a rising incidence and the early occurrence of metastases. Because of its pronounced resistance to therapies in advanced stages of disease, extensive research is done to find new effective therapeutic concepts.

We report a 62-year-old woman who was diagnosed with acral lentiginous melanoma of the left foot and positive sentinel lymph node in October 2005. After resection of the primary skin melanoma and complete lymph node dissection of the left groin, multiple satellite and in-transit metastases appeared on the left leg 11 months later. The patient was subjected to different systemic therapies, including two cycles of dacarbazine, 2 months of peptide vaccination, and four cycles of a chemotherapy with treosulfan and cytarabine, all of these without success. After resection of new lymph node metastases in the left groin in June 2007, an ablation of multiple cutaneous metastases on the left thigh with...


Paclitaxel Optical Coherence Tomography Sorafenib Macular Edema Acetazolamide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Joshi MM, Garretson BR (2007) Paclitaxel maculopathy. Arch Ophthalmol 125(5):9–10CrossRefGoogle Scholar
  2. 2.
    Hofstra LS, de Vries EGE, Willemse PHB (1997) Ophthalmic toxicity following paclitaxel infusion. Ann Oncol 8:1053–1054PubMedCrossRefGoogle Scholar
  3. 3.
    Murphy CG, Walsh JB, Hudis CA, Lake D, Theodoulou M (2010) Cystoid macular edema secondary to nab-paclitaxel therapy. J Clin Oncol 28(33):e684–e687PubMedCrossRefGoogle Scholar
  4. 4.
    Ito S, Okuda M (2010) A case of cystic maculopathy during paclitaxel therapy. Nippon Ganka Gakkai Zasshi 114(1):23–27PubMedGoogle Scholar
  5. 5.
    Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27:2823–2830PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Kerstin Maria Meyer
    • 1
    Email author
  • Thomas Klink
    • 2
  • Selma Ugurel
    • 1
  • Eva-Bettina Bröcker
    • 1
  1. 1.Department of DermatologyJulius-Maximilians UniversityWürzburgGermany
  2. 2.Department of OphthalmologyJulius-Maximilians UniversityWürzburgGermany

Personalised recommendations